Bladder Cancer

Among patients with muscle-invasive bladder cancer, perioperative Imfinzi to chemotherapy doesn’t have a detrimental effect on patient-reported outcomes.

The addition of Tecentriq to BCG therapy did not significantly improve outcomes for patients with non–muscle-invasive bladder versus BCG alone.

Dr. Patrick J. Hensley explains non-muscle invasive bladder cancer, bladder-preserving treatments, trial eligibility, novel therapies and research priorities for patients.

In September 2025, the FDA approved new treatments for breast, bladder and prostate cancers, plus biosimilars and a subcutaneous immunotherapy option.

Urothelial carcinoma, the most common type of bladder cancer, is explained from diagnosis to treatment.

This issue of CURE highlights personal stories and expert insights, from living with multiple diagnoses to self-advocacy, nutrition and survivorship care.

The FDA has approved Inlexzo for adults with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ.

TAR-200 eliminated tumors in 82% of patients in a phase 2 trial for patients with high-risk non-muscle-invasive bladder cancer.

PredicineCARE, a urine-based test, is under FDA review as a companion diagnostic for bladder cancer, building on previous data and biomarker insights.

This guide provides an overview of bladder cancer, from diagnosis to treatment, helping patients understand options, manage side effects, and plan care.

Alpha1H shows benefit in non-muscle invasive bladder cancer, shrinking tumors and boosting the immune system with manageable side effects.

Keytruda and Padcev generated promising topline results for those with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.

Clinical trial updates in cancer care include a remote study in small cell lung cancer and new findings in ovarian, solid tumor, and urothelial cancers.

In a phase 3 trial, 72.2% of patients with recurrent low-grade bladder cancer kept complete response at 24 months after Zusduri treatment.

CURE spoke with experts about radical cystectomy, or surgical removal of the bladder, for patients with bladder cancer.

Patients with high-risk bladder cancer reported similar quality of life when treated with sasanlimab plus BCG versus BCG alone, new study data showed.

Treatment with Zusduri had a median duration of response of 3.5 years and event-free survival of two years in low-grade intermediate-risk bladder cancer.

FDA grants priority review to TAR-200, which demonstrated an 82% complete response in high-risk bladder cancer unresponsive to Bacillus Calmette-Guérin.

New clinical trials are advancing in hard-to-treat cancers, offering targeted and less toxic options for patients with limited treatment paths.

Nine years after my bladder cancer diagnosis, I reflect on its recurrence, caregiving, grief, and my new life with leukemia and renewed gratitude.

The FDA has granted approval to UGN-102 for use in patients with low-grade intermediate-risk non-muscle-invasive bladder cancer.

Dr. Joshua K. Sabari and Dr. Daniel V. Araujo provide expert insights into genitourinary cancer updates from ASCO 2025.

Dr. Guru Sonpavde discusses the CheckMate 901 trial evaluating Opdivo plus Yervoy for those with cisplatin-ineligible, metastatic urothelial carcinoma.

Antihistamines may be associated with survival improvement in patients with metastatic urothelial carcinoma receiving Tecentriq.

Dr. Daniel P. Petrylak sits down with CURE during Bladder Cancer Awareness Month to discuss key topics for patients with the disease.